14 December 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its interim results for the six months ended 30 September 2017.
To view the Interim Results Presentation slide deck please click here.
To log on to view the webcast of the analyst presentation please click here.
FDA approves ReNeuron’s IND application to commence a Phase IIb clinical trial in the US in stroke disability
14 December 2017: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce that the FDA has given regulatory approval for the Company to commence a Phase IIb clinical study in the US with its CTX cell therapy candidate for stroke disability.
8 December 2017: ReNeuron Group plc (AIM: RENE) , a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has established an office in Boston, MA, USA.
13 November 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, intends to announce its interim results for the six months ended 30 September 2017 on Thursday 14 December 2017.
Data Safety Monitoring Board gives approval for ongoing retinitis pigmentosa clinical trial to progress into Phase II element based on short term safety data
8 November 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today provides an update regarding the Company’s ongoing Phase I/II clinical trial of its hRPC cell therapy candidate for the blindness-causing disease, retinitis pigmentosa (“RP”).
Long term data from Phase II stroke clinical trial confirm positive results seen after three months.
Results indicate that CTX cell therapy has potential to improve long term outcomes in disability, dependence and motor function in disabled stroke patients.
31 October 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today provides an update regarding the Company’s Phase II clinical trial (PISCES II) of its CTX cell therapy candidate for stroke disability and, in addition, an update regarding its global clinical and regulatory development strategy for the stroke programme.
27 October 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is the lead industry participant in a new grant award from the Welsh Government to advance its emerging exosome therapy platform.
11 October 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at major scientific conference.
6 September 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at today’s Annual General Meeting were duly passed.
6th September 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting.
To see the slides accompanying the presentation made at the AGM please click here.
For our archived news, click here
